Live Attenuated Vaccines are a type of vaccine that contains weakened forms of the pathogen, typically viruses, which are still capable of replicating within the body but cause little to no disease. These vaccines are created by passaging the virus through a series of host cells or by genetically modifying the virus to reduce its virulence while maintaining its ability to stimulate an immune response. Live attenuated vaccines offer several advantages over other types of vaccines. They closely mimic natural infection, triggering a robust immune response that provides long-lasting immunity. In many cases, a single dose of a live attenuated vaccine is sufficient to confer protection against the targeted disease, eliminating the need for booster doses.
Some of the most well-known live attenuated vaccines include those for measles, mumps, rubella (MMR), varicella (chickenpox), yellow fever, oral polio vaccine (OPV), and rotavirus. These vaccines have been highly effective in controlling and even eradicating diseases that were once widespread and deadly. Despite their effectiveness, live attenuated vaccines may not be suitable for certain individuals, such as those with weakened immune systems or pregnant women, who may be at risk of developing severe or adverse reactions. Additionally, live attenuated vaccines require careful handling and storage to maintain their potency, as they can lose efficacy if exposed to high temperatures or mishandled during storage and administration.
Overall, live attenuated vaccines have been instrumental in reducing the burden of infectious diseases and saving countless lives worldwide. By closely mimicking natural infection and stimulating a robust immune response, these vaccines play a crucial role in protecting individuals and communities from a variety of preventable diseases.
Title : A promising novel approach to DNA vaccines
Khursheed Nadeem Anwer, IMUNON, United States
Title : Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration
David Craig Wright, D4 Labs, LLC, United States
Title : The importance of post-marketing surveillance and real-world data for a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Advances in vaccines: Revolutionizing disease prevention
Delia Teresa Sponza, Dokuz Eylul University, Turkey